Summa Health System/Northeast Ohio Universities College of Medicine, Division of Plastic and Reconstructive Surgery, Akron, Ohio 44304, USA.
J Plast Reconstr Aesthet Surg. 2010 Aug;63(8):1344-8. doi: 10.1016/j.bjps.2009.07.032. Epub 2009 Aug 22.
Keloid management is faced with high recurrence rates. Keloid fibroblasts lack the normal negative feedback mechanism resulting in an exuberant scar formation. Alloderm doesn't undergo the same proliferative process as keloidal scar dermis.
To evaluate Alloderm as a treatment modality for keloids
A retrospective chart review of six patients with a total of eight large recurrent keloids was performed. Patients were treated with excision of the keloid followed by placement of Alloderm. Each patient was evaluated for recurrence and complications.
During follow-up ranging from 1 month to 4(1/2) years there were 0% recurrences. Two out of 8 (25%) had residual induration. one of the two patients with residual induration, required an intralesional injection of kenalog at 6 months post-op.
Our results from this small study show that with the use of Alloderm after keloid excision, recurrence is low. Further study is warranted.
瘢痕疙瘩的治疗面临着高复发率。瘢痕疙瘩成纤维细胞缺乏正常的负反馈机制，导致过度的瘢痕形成。Alloderm 不会像瘢痕疙瘩真皮一样经历同样的增殖过程。
评估 Alloderm 作为瘢痕疙瘩的治疗方法。
对 6 名患者的 8 个大型复发性瘢痕疙瘩进行了回顾性图表分析。患者接受了瘢痕疙瘩切除，然后放置了 Alloderm。对每位患者的复发和并发症进行了评估。
在 1 个月至 4 年半的随访期间，无复发。8 例中有 2 例（25%）有残余硬结。2 例有残余硬结的患者中，1 例在术后 6 个月需要进行曲安奈德瘤内注射。
我们的小样本研究结果表明，在切除瘢痕疙瘩后使用 Alloderm，复发率较低。需要进一步研究。
